Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
15
15 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- HSK31858Phase 33 trials
Haisco Pharmaceutical Group Co., Ltd. · Non-cystic Fibrosis Bronchiectasis, Asthma Bronchiale, Bronchiectasis
- VX-121D-IVA, CTP-656Phase 33 trials
Vertex Pharmaceuticals · Cystic Fibrosis
- GalvokimigUCB9741Phase 23 trials
UCB · Chronic Obstructive Pulmonary Disease With Chronic Bronchitis, Atopic Dermatitis, Non-cystic Fibrosis Bronchiectasis
- ANG003Phase 21 trial
Anagram Therapeutics, Inc. · Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
- ARCT-032Phase 21 trial
Arcturus Therapeutics, Inc. · Cystic Fibrosis, CFTR Gene Mutation
- BX004Combination of nebulized bacteriophages targeting Pseudomonas aeruginosaPhase 21 trial
BiomX Ltd · Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
- CMTX-101Phase 21 trial
Clarametyx Biosciences, Inc. · Persistent Infection, Cystic Fibrosis
- CSL787Phase 21 trial
CSL Behring · Non-cystic Fibrosis Bronchiectasis
- ETD001Phase 21 trial
Enterprise Therapeutics Ltd · Cystic Fibrosis
- NHS7108Phase 21 trial
Aimmune Nestlé Health Science US R&D, LLC · Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality
- RCT2100Phase 21 trial
ReCode Therapeutics · Cystic Fibrosis
- RESP302Phase 21 trial
Thirty Respiratory Limited · Non-Cystic Fibrosis Bronchiectasis
- RESP303Phase 21 trial
Thirty Respiratory Limited · Non-Cystic Fibrosis Bronchiectasis
- RSP-1502Phase 21 trial
Respirion Pharmaceuticals Pty Ltd · Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
- SPL84Phase 21 trial
SpliSense Ltd. · Cystic Fibrosis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.